Last reviewed · How we verify
NCT02492789
A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients
Phase 1 trial testing INCSHR01210 injection in Solid Tumors and Hematologic Malignancy in 49 participants. Completed in 5 July 2019.
1 March 2019
Quick facts
| Lead sponsor | Atridia Pty Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 49 |
| Start date | 1 September 2015 |
| Primary completion | 1 March 2019 |
| Estimated completion | 5 July 2019 |
| Sites | 5 locations across Australia |
Drugs / interventions tested
- INCSHR01210 injection — full drug profile →
Conditions studied
- Solid Tumors and Hematologic Malignancy — all drugs for Solid Tumors and Hematologic Malignancy →
Sponsor
Atridia Pty Ltd. — full company profile →
Who can join
18 and older, any sex, with Solid Tumors and Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, multicenter, non-randomized, dose escalation and tumor-expansion phase I trial to evaluate safety and tolerability of INCSHR01210 in patients with advanced solid tumors. The trial will enroll subjects with advanced solid tumor who have failed current standard anti-tumor therapies.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.
Tan S, Chen D, Liu K, He M, et al · · 2016 · cited 33× · PMID 27815822 · DOI 10.1007/s13238-016-0337-7 -
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia.
Lickliter JD, Gan HK, Voskoboynik M, Arulananda S, et al · · 2020 · cited 29× · PMID 32256049 · DOI 10.2147/dddt.s243787 -
Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.
Liu L, Liu Y, Gong L, Zhang M, et al · · 2020 · cited 6× · PMID 33092443 · DOI 10.1080/15384047.2020.1829265 -
The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
· 2020
Verify or expand the search:
- PubMed search for NCT02492789
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Atridia Pty Ltd. trials
Trials by the same sponsor.
- NCT07358377 — To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negati · Phase 1 · not yet recruiting
- NCT07390747 — A Trial of SHR-2173 in Healthy Volunteers · Phase 1 · recruiting
- NCT07238647 — A Trial of HRS-5817 in Obese Participants · EARLY_PHASE1 · recruiting
- NCT07078695 — A Trial of SHR-1139 in Healthy Volunteers · Phase 1 · active not recruiting
- NCT07033455 — A Trial of HRS-1893 in Healthy Volunteers · EARLY_PHASE1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02492789 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Atridia Pty Ltd.
- Last refreshed: 30 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02492789.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing